Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - News - Generic Drugs - September 19, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 79     Next >>     Go To Page:

9/19/17 - Amgen and Allergans anti-cancer biosimilar Mvasi receives FDA approval [All Iraq News Agency (AIN)]
Co-developed by Amgen and Allergan, Mvasi is the first anti-cancer biosimilar to be approved by the FDA and is largely similar to Avastin. Amgen research and development executive vice-president Dr Sean E. Harper said: The approval of Mvasi marks a significant milestone for healthcare practitioners and patients as the first anti-cancer biosimilar..
9/19/17 - Beximco Pharma commences export to Canada
Release date- 17092017- Beximco Pharmaceuticals Limited, the fast growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Olopatadine, an ophthalmic product for treating the symptoms of eye allergy, to Canada. According to IMS data, the current market size for...
9/19/17 - CME Outfitters Launches New Online Biosimilars Hub
CME Outfitters, a leading accredited provider in continuing medical education, has launched a unique Biosimilars Education Hub where clinicians can find up to date listings of all upcoming and currently available activities on biosimilar agent. In addition to these free educational activities, the hub also features resources that clinicians can use
9/19/17 - CME Outfitters Offering Two New Snacks on the Use of Biosimilars in the Treatment of Inflammatory Diseases
CME Outfitters, LLC, a leading accredited provider in continuing medical education, announces the launch of a new pair of CME Snacks discussing the newly approved biosimilar, infliximab, and its ability to treat a variety of inflammatory diseases. While biosimilars have been available in Europe since 2005, the first biosimilar monoclonal antibody i
9/19/17 - Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S.
Ketorolac Tromethamine Injection has been developed in collaboration with Caplin Point Laboratories Ltd and is manufactured at their FDA approved site. After the successful launch of Nityr? tablets last month from our Orphan Drugs Division, we are proud to be announcing the first product from our Generics Division. said Steve Fuller, Head o
9/19/17 - FDA approves first biosimilar for the treatment of cancer
Release date- 18092017- The U.S. Food and Drug Administration today approved Mvasi as a biosimilar to Avastin for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. 'Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high,
9/19/17 - Fosun accepts lower stake in Indian pharma [China Daily: Africa Weekly]
Shanghai- based Fosun Pharmaceutical Group will downsize its planned acquisition stake in the Indian generic drugmaker Gland Pharma to 74 percent from the previously announced 86 percent, according to a Fosun Pharmaceutical announcement released on Monday. Fosun Pharmaceutical will pay about $1.09 billion for the acquisition? the biggest takeover
9/19/17 - Glenmark looks to file up to 25 product applications annually [Arab Finance (Egypt)]
Glenmark Pharmaceuticals plans to file close to 25 product applications annually over the next five years, the company`s chairman has said. The Mumbai- based firm also expects to launch nearly 20 products annually. "We expect to file 20-25 abbreviated new drug applications each year over the next five years and launch 10-20 products annually," Gle
9/19/17 - GLENMARK MAY FILE 25 PRODUCT APPLICATIONS/YEAR
Glenmark Pharmaceuticals Limited of Mumbai is planning to file 25 abbreviated new drug applications per year till 2022.
9/19/17 - Glenmark receives ANDA approval for Desonide Ointment [India Infoline News Service]
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food& Drug Administration for Desonide Ointment, 0.05%, the generic version of Desonide Ointment, 0.05%, of Perrigo New York Inc. Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food& Drug Administration for Desonide Ointm
9/19/17 - Global Biosimilars Market Growth, Trends & Forecasts 2017-2022 - Research and Markets
The "Global Biosimilars Market-Growth, Trends& Forecasts 2017- 2022" report has been added to Research and Markets' offering. The Global Biosimilars Market was valued at USD 5237.0 currently and is projected to reach USD 28200.0 million by 2020, at a CAGR of 40.3% during the forecast period from 2015 to 2021.. Reddys, Teva Pharmaceuticals, Hospira,
9/19/17 - Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin 24 FE Tablets
Release date- 18092017- HERTFORDSHIRE, England and PITTSBURGH- Mylan N.V., today announced the U.S. launch of Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, 1 mg/20 mcg, which is indicated for use by women to prevent pregnancy. Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tabl
9/19/17 - New Initiative Creates Scalable Solutions to Improve Care of Patients With Multiple Chronic Conditions
Mount Sinai Hospital issued the following news release:. The initiative was announced to an audience of public health leaders at the World Economic Forum's Sustainable Development Impact Summit. TEVA Pharmaceutical Industries Ltd., the world's largest generic drug company, and Mount Sinai Health System, one of the largest hospital groups in the Uni
9/19/17 - New Live CME Outfitters Webcast on Biosimilars to Treat Inflammatory Disease Launching Soon
CME Outfitters, LLC, a leading accredited provider in continuing medical education, is excited to announce a new live webcast, where participant questions from two free CME Snacks on the topic of biosimilars to treat inflammatory diseases. Leonard Calabrese, DO, will be going in-depth with the questions provided to discuss the interchangeability, e
9/19/17 - Roche cancer blockbusters face competition in US and EU [T-break Tech (Middle East)]
The FDA has separately approved Amgens biosimilar of another Roche cancer blockbuster, Avastin. Amgen and Allergan have also filed their Herceptin biosimilar in the US and EU this year and clinical trial results presented at ESMO last week suggest the drug could actually be slightly more effective than the originator, based on a measure of patholog
9/19/17 - Samsung Bioepis on track to launching first Herceptin biosimilar in Europe [T-break Tech (Middle East)]
It is the first biosimilar copy of Herceptin to obtain such backing in Europe. The EMAs endorsement sets Samsung Bioepis on track to bringing the first biosimilar version of Herceptin to Europe and challenging sales of Herceptin, which generated around $6.8 billion in global revenue for Roche in 2016.. We are proud to see Ontruzant become the first
9/19/17 - Teligent, Inc. Announces FDA Approval of Triamcinolone Acetonide Cream USP, 0.1%
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has received approval of the Company s abbreviated new drug application from the U.S. Food and Drug Administration of Triamcinolone Acetonide Cream USP, 0.1%. Triamcinolone Acetonide Cream USP, 0.1% is Teligent s fifth FDA approval in 2017,?
9/19/17 - US FDA approves Amgen and Allergan`s Avastin biosimilar [Sport360]
Amgen developed Mvasi in collaboration with Allergan under a deal signed in 2010. An Amgen spokeswoman told us "In the collaboration with Allergan, Amgen has primary responsibility for the development, manufacture and initial commercialization of the products; whereas Allergan will provide funding over the course of development as well as expertise
9/18/17 - Fosun to acquire Gland Pharma, with smaller stake [China Daily: Africa Weekly]
Shanghai Fosun Pharmaceutical Group announced on Monday it will acquire an approximately 74 percent stake in the Indian generic drug maker Gland Pharma, down from the 86 percent stake announced last July. Fosun Pharmaceuticals will pay about $1.09 billion for the acquisition. It is the first injectable drugs manufacturer in India to be approved by
9/18/17 - Genentech Receives Blow by FDA in Cancer Drug Avastin Biosimilar Battle, an Industrial Info News Alert
Researched by Annette Kreuger, Industrial Info Resources Biological drug maker Genentech, the developer of the blockbuster cancer drug Avastin, was dealt a stunning blow on September 14 when the U.S. Food and Drug Administration approved a biosimilar. For details, view the entire article by subscribing to Industrial Info's Premium Industry News
9/18/17 - Generic Drugs Market is Anticipated to Show Growth by 2022
ReportsMonitor.com has added a new report to its database The Future of Generic Drugs and Strategies for Commercial Success Summary: GBI Research's latest report "The Future of Generic Drugs and Strategies for Commercial Success&a...
9/18/17 - Glancy Prongay & Murray LLP Continues Investigation on Behalf of Teva Pharmaceutical Industries Ltd. Investors
By a News Reporter-Staff News Editor at Pharma Business Week Glancy Prongay& Murray LLP continues its investigation on behalf of Teva Pharmaceutical Industries Ltd. investors concerning the Company and its officers' possible violations of federal securities laws. On August 2, 2016, Teva finalized its acquisition of Allergan plc's generics busines
9/18/17 - Inventiva's IVA337 Given Generic Name Lanifibranorby the World Health Organization (WHO)
Inventiva, a biopharmaceutical company developing innovative breakthrough therapies, particularly for the treatment of fibrotic diseases, today announced that the World Health Organization has granted it the international non-proprietary name lanifibranor for IVA337, its leading drug candidate, currently is in Phase IIb development for both...
9/18/17 - New Initiative Creates Scalable Solutions to Improve Care of Patients With Multiple Chronic Conditions
The initiative was announced to an audience of public health leaders at the World Economic Forum's Sustainable Development Impact Summit. TEVA Pharmaceutical Industries Ltd., the world's largest generic drug company, and Mount Sinai Health System, one of the largest hospital groups in the United States, aim to gain new data and insights into interv
9/18/17 - Perrigo Announces Tentative FDA Approval For The Generic Version Of Acanya Gel
Perrigo Company plc today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Acanya topical gel 1.2%/ 2.5%. Perrigo previously settled litigation with Dow Pharmaceutical Sciences, Inc. and Valeant Pharmaceuticals North America LLC for this product. Perrigo Company plc, a leading g
Articles(s): 1 - 25 of 79     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415